Artesunate    (DrugBank: Artesunate)

1 disease
IDDisease name (Link within this page)Number of trials
66IgA nephropathy1

66. IgA nephropathy    [ 199 clinical trials,   214 drugs,   (DrugBank: 57 drugs),   32 drug target genes,   128 drug target pathways]
Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 199 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000038104
2020-09-012020-09-10Efficacy and safety of Artesunate for patients with IgA nephropathy: a multicenter, double-blind, randomized, placebo-controlled trial.Efficacy and safety of Artesunate for patients with IgA nephropathy: a multicenter, double-blind, randomized, placebo-controlled trial. IgA nephropathyGroup 1:Artesunate 100mg (50mg/Bid);Group 2:Artesunate 50mg (25mg/Bid);The control group:Placebo;Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese MedicineNULLRecruitingBothGroup 1:40;Group 2:40;The control group:40;China